Makes DNA sequencing machines that read genomes using a chemistry and hardware design no other company uses.
At a glance
- Depends onDownstream position: depends on 8 industries, supplies 3
- ScaleMarket cap is above the global median
Makes DNA sequencing machines that read genomes using a chemistry and hardware design no other company uses.
What this company is and how it runs — written from structure, not news.
MGI Tech makes DNA sequencing machines that work by converting individual DNA molecules into compact balls of identical copies — a method called rolling circle amplification — and then landing each ball into a precisely etched hole on a flow cell surface so the sequencer can read it. Those holes, called nanowells, have to be patterned using semiconductor lithography equipment inside a dedicated cleanroom, and their dimensions are matched so tightly to the DNA nanoball size that the flow cell and the chemistry are effectively one inseparable design. Clinical laboratories that have run regulatory filings against a specific MGI platform cannot swap to a different sequencer without resubmitting those filings, which means each validated customer site locks in the reagents, the bioinformatics pipeline, and the service contract all at once. The whole structure rests on the ability to keep etching nanowells at the right tolerances, so if US export controls cut off access to the advanced lithography tools that make that fabrication possible, the chemistry loses its physical substrate and the clinical lock-in built on top of it unravels at the factory rather than at the customer.
How does this company make money?
The company sells sequencer machines outright, ranging from smaller benchtop units to large production-scale systems. After the sale, it earns recurring income from reagent kits that customers must buy each time they run a sequencing job — the more they sequence, the more kits they need. It also charges software licensing fees for its bioinformatics analysis tools, and collects service contract fees for ongoing instrument maintenance and technical support.
What makes this company hard to replace?
Clinical laboratories have already filed regulatory submissions for diagnostics that name a specific DNBSEQ platform configuration — switching to a different sequencer means resubmitting those filings, which takes significant time and money. Customers also have multi-year reagent supply contracts with volume commitments they would have to unwind. On top of that, the bioinformatics software is woven into each laboratory's own information systems, so swapping the sequencer means rebuilding the data pipeline too.
What limits this company?
The nanowells in each flow cell have to be etched inside a dedicated cleanroom using semiconductor fabrication equipment. That step cannot be handed off to another manufacturer without giving away the exact nanowell design, and it cannot be sped up just by making more reagents. The cleanroom's output sets a hard ceiling on how many flow cells can be produced, which in turn limits how much sequencing the company's customers can do — no matter how high demand gets.
What does this company depend on?
The company cannot operate without its DNBSEQ flow cell semiconductor fabrication facilities, which etch the nanowells. It also needs rolling circle amplification enzyme licenses, specialized fluorescent nucleotide chemistry, temperature-controlled reagent delivery systems, and China FDA medical device manufacturing permits to sell its products legally.
Who depends on this company?
Chinese genomics research institutes rely on it for access to domestically-produced high-throughput sequencing. Agricultural genomics companies across Asia use DNBSEQ platforms to analyze crop genomes, and if supply stopped they would have no direct local replacement. Clinical laboratories running DNBSEQ systems would face gaps in both reagent supply and instrument servicing, which could interrupt diagnostic work tied to regulatory submissions already built around this platform.
How does this company scale?
The sequencing chemistry recipes and software algorithms can be copied to additional sequencer units at almost no extra cost — once developed, they cost nearly nothing to reproduce. What does not scale easily is the flow cell factory: building more cleanroom capacity requires significant investment, specialized semiconductor expertise, and time, and the proprietary nanowell patterning process cannot simply be handed to a contract manufacturer.
What external forces can significantly affect this company?
US export controls on semiconductor manufacturing equipment are the most direct external threat, because restrictions on advanced lithography tools would cut off the supply of properly etched flow cells. Chinese government regulations on genomics data sovereignty push hospitals and research institutes toward domestic sequencing infrastructure, which can help demand but also brings regulatory obligations. Rising costs of rare earth elements used in the fluorescent sequencing chemistry add pressure to the cost of each reagent kit.
Where is this company structurally vulnerable?
If the US tightens export controls on advanced semiconductor lithography equipment — the tools used to etch the nanowells — the company could lose the ability to manufacture flow cells at the precise dimensions the chemistry requires. Without correctly sized nanowells, the DNA balls have no surface to land on, the sequencing chemistry cannot run, and every product built on top of that chemistry stops working at the same time.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
CompanyGraph